The Impact of Proteomics in the Understanding of the Molecular Basis of Paclitaxel-Resistance in Ovarian Tumors

E-ISSN： 1873-5576|12|8|987-997

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.12, Iss.8, 2012-10, pp. : 987-997

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation

Current Cancer Drug Targets, Vol. 3, Iss. 1, 2003-02 ,pp. : 1-19

Bentham Science Publishers

Access to resources Recommend Favorite

Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics

Current Drug Targets, Vol. 7, Iss. 4, 2006-04 ,pp. : 387-395

Bentham Science Publishers

Access to resources Recommend Favorite

The molecular basis of group B meningococcal serum resistance

By Ram S. Mackinnon F. Gulati S. Vogel U. Gorringe A. Rice P.

Immunopharmacology, Vol. 49, Iss. 1, 2000-08 ,pp. : 73-73

Elsevier

Access to resources Recommend Favorite

Paclitaxel poliglumex for ovarian cancer

By Galic Vijaya L Wright Jason D Lewin Sharyn N Herzog Thomas J

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 813-821

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel-Loaded Poly(n-butylcyanoacrylate) Nanoparticle Delivery System to Overcome Multidrug Resistance in Ovarian Cancer

By Ren Fei Chen Ruda Wang Ying Sun Yabin Jiang Yaodong Li Guofeng

Pharmaceutical Research, Vol. 28, Iss. 4, 2011-04 ,pp. : 897-906

Springer Publishing Company

Access to resources Recommend Favorite